A man of commitment
6 February 2015
Melanoma patient Joel Allsop was congratulated today on completing his participation in the international surgical clinical trial, known as MSLT-II. He was the first person in the world to complete the 10 years of follow-up for this trial. This outstanding commitment was acknowledged by Melanoma Institute Australia’s Executive Director, Professor John Thompson, who has been involved in the trial and Joel’s care from the beginning.
At age 33, Joel was diagnosed with stage 3 melanoma originating from a small mole on his thigh. He was referred to Professor Thompson in December 2004 and was invited to participate in the clinical trial. The MSLT-II trial is assessing whether complete lymph node dissection or monitoring with ultrasound is the most effective way at treating patients who have a positive sentinel lymph node biopsy. Interim findings from the study are expected in the next year or so, with the final results being published after the decade-long follow-up of the last patient is undertaken. This international trial has only recently completed recruiting and has 1937 patients from around the world involved in the trial.
Joel was randomised on the trial to receive follow-up with ultrasound. His commitment throughout the past decade has been regular appointments and ultrasounds ranging from every 4 months in the beginning to every year after 5 years. A Sydney local for most of the decade, Joel spent 2 years during the trial flying to Sydney from Perth every 6 months to stay on the trial.
“I am a stubborn man! I will see things through to the end!” says Joel when asked about why he stayed on the trial for the whole decade.
With a family history of cancer, Joel realised that his participation would have long-lasting benefits beyond his own melanoma journey. “I knew I was getting the best possible care on the trial, but I also realised that my participation would have benefits to melanoma patients around the world.”
A decade on, Joel is healthy and his melanoma hasn’t progressed. Although getting melanoma was a “surreal blur” in the beginning, his journey has now given him a fresh perspective on life.
“Having melanoma has helped me re-evaluate what is important in life and given me clearer perspective,” says Joel. “Two years ago I was made redundant, and instead of thinking that the end of the world had come, I thought ‘well, things could be worse!’”.
This week, Melanoma Institute Australia hosted the first of six
Federal government urged
We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!
Lauren O'Brien tells us why she's running for a cause close to her heart
MIA could not do what we do without the incredible support and effort of our community fundraisers. We’d like to highlight some of the wonderful events organised by our community in
An international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has discovered that a drug traditionally used to treat a
Researchers from Melanoma Institute Australia took centre stage at the American Society of Clinical Oncology Annual Meeting in Chicago. Results presented by MIA’s contingent have the potential to create better patient outcomes and change the way advanced melanoma
Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.
“I’m the age Emma was when she passed away. It almost feels
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.
MIA had four winners in the 2017 Premiers Awards. Find out how winning has influenced their work over the past year.
Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects
Almost $9 million of new funding was awarded to 13 ground-breaking cancer research projects at the 2019 Cancer Council NSW Research Awards.
Georgina V. Long is co-medical director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research. She is the first woman president of the Society for Melanoma Research.
Quintessential Aussie girl and media personality Sophie Monk has been announced as a National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.
Melanoma March is thrilled to introduce Ricky as our official Principal Partner for 2019!
World record holder, Olympian and Australian swimming champion Cate Campbell has been announced as National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
MIA's expertise was essential to a recent Nature publication spearheaded by Perth’s Telethon Kids Institute and The University of Melbourne.
MIA is delighted to be hosting the MD Anderson pathologist on his first ever trip to Australia.